PatientsForce
Company News · Policy & Public-Private Collaboration2026-11-10

The Last Mile for Hard-to-Access Paediatric Medicines: PatientsForce Receives MOHW Commendation

The Last Mile for Hard-to-Access Paediatric Medicines: PatientsForce Receives MOHW Commendation

The Ministry of Health and Welfare (MOHW) held the 2026 results presentation for its Program for Excellence in Child Health Care on 10 November. PatientsForce received a letter of commendation from the ministry, recognised as a partner supplier for clinically necessary medicines and medical devices that are hard for children to obtain.

A structural gap in paediatric medicines

Demand for paediatric dosage forms and device sizes is small and dispersed, so manufacturers struggle to recover the cost of registration and post-market maintenance. The result is a persistent gap: commercially unviable, clinically indispensable. When no locally licensed product exists, clinical teams must apply to the Food and Drug Administration for special approval to import or manufacture under the Pharmaceutical Affairs Act — the route known internationally as expanded access or named patient supply. The bottleneck usually sits upstream of review: identifying an overseas source, securing manufacturer authorisation and regulatory documentation, and arranging transport that meets cold chain and GDP conditions.

A public-private response

Since 2021 the MOHW has operated a dispatch centre for clinically necessary paediatric medicines and devices that are hard to obtain, linking 183 hospitals, 17 medical societies and 47 suppliers. It runs joint procurement based on a nationwide demand survey and acts as the single applicant for special approvals. Filings for this category fell from 683 submitted separately by individual hospitals in 2021 to 50 submitted centrally by the end of 2025 — less duplicated administration, and dispersed demand aggregated to a scale that can be negotiated.

The MOHW's 2026 results presentation recognised 156 medical institutions and partners; PatientsForce was named a partner supplier for clinically necessary paediatric medicines and devices that are hard to obtain.
The MOHW's 2026 results presentation recognised 156 medical institutions and partners; PatientsForce was named a partner supplier for clinically necessary paediatric medicines and devices that are hard to obtain.

What a partner supplier adds

PatientsForce joined the programme in 2026, taking on the segment the dispatch centre cannot absorb internally: cross-border sourcing, assembling regulatory documentation, negotiating quotations and lead times, and delivering with an auditable trail. These cases are fragmented, tiny in volume and tightly timed — uneconomic at the scale of a general importer, yet decisive in whether a child receives a medicine inside the treatment window.

Clinical teams can review filing requirements at Expanded Access Programs, or check patient support programs for an existing match.

Sources